Bone targeted delivery of salmon calcitonin hydroxyapatite nanoparticles for sublingual osteoporosis therapy (SLOT)

Kotak, Darsheen J.; Devarajan, Padma V.

doi:10.1016/j.nano.2020.102153

Cited by 28 publications

(19 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sublingual administration is a promising route for drugs whose absorption by the oral route is sub-optimal due to hepatic first-pass metabolism (Kotak & Devarajan, 2020 ; Leal-Júnior et al, 2020 ). Moreover, it usually provides rapid onset of action due to the high vasculature of the oral mucosa in addition to the ease of administration of sublingual tablets.…”

Section: Introductionmentioning

confidence: 99%

Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study

Naguib

Makhlouf

2021

Drug Delivery

View full text Add to dashboard Cite

Flibanserin (FLB) was approved by FDA for the treatment of pre-menopausal female hypoactive sexual desire disorder (HSDD). FLB suffers from low oral bioavailability (33%) which might be due to hepatic first-pass metabolism in addition to its poor aqueous solubility. The sublingual route could be a promising alternative for FLB due to the avoidance of enterohepatic circulation. However, the drug needs to dissolve in the small volume of saliva in order to be absorbed through the sublingual mucosa. Therefore, FLB nanocrystals were prepared by sono-precipitation technique according to 2 3 full factorial design. FLB-nanocrystals were formulated using two surfactants (PVP K30 and PL F127) in two different amounts (200 and 400 mg) and the volume of ethanol was either 3 or 5 mL. Nanocrystal formulation was optimized according to the desirability function to have a minimum particle size, zeta potential, polydispersity index, and maximum saturated solubility. The optimized formula had a particle size of 443.12 ± 14.91 nm and a saturated solubility of 23.27 ± 4.62 mg/L which is five times the saturated solubility of FLB. Nanocrystal dispersion of the optimized formula was solidified by freeze-drying and used to prepare rapidly disintegrating sublingual tablets containing Pharmaburst ® as superdisintegrant. Sublingual tablet formulation with the shortest disintegration time (36 s) was selected for the in vivo study. FLB nanocrystal-based sublingual tablets exhibited a two-fold increase in bioavailability with a faster onset of action compared to the commercially available oral formulation. These findings prove the potential application of FLB nanocrystal-based sublingual tablets in the treatment of HSDD.

show abstract

Section: Introductionmentioning

confidence: 99%

Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study

Naguib

Makhlouf

2021

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…In this study, we first demonstrated that the expression of miR- Osteoporosis, especially postmenopausal osteoporosis, has a severe influence in aging population [21]. In current, several drugs such as bisphosphonates, calcitonin and so on have been used to slow the process of bone loss [22][23]. Moreover, administration of stem cells could prevent or reverse the osteoporosis and reduce the susceptibility of bone fractures.…”

Section: Discussionmentioning

confidence: 95%

Overexpression of miR-29b Partially Rescued the Osteogenic Differentiation and Osteogenesis Ability of Ovx-BMSCs

Jing-An¹

2021

AJBSR

View full text Add to dashboard Cite

show abstract

“…Various methods can be applied to prepare and functionalize CBNMs, including a simple, mild liquid-phase mineralization reaction. ,,− This provides an opportunity to achieve uniform nanomorphology and diversified functionalization of CBNMs using many hydrophilic drugs and organic ingredients via mineralization reactions. CBNMs, especially CaP, are also structurally able to accept many ionic substitutions, such as strontium, ,− cobalt, boron and europium .…”

Section: Cbnms For Osteoporosis Treatmentmentioning

confidence: 99%

“…Various preparation methods allow for the construction of different forms of antiosteoporotic CBNMs. The preparation methods discussed here include coprecipitation, ,,,− ,,,− sol–gel, ,− ,,− ,− hydrothermal, ,,, electrochemical deposition, ,, electrostatic spray deposition, vapor diffusion, sonochemical synthesis, and physical crushing. − Each preparation method has unique advantages and is accordingly suitable for the preparation of specific forms of CBNMs. The physicochemical properties of CBNMs prepared by different methods are summarized in Table .…”

Section: Cbnms For Osteoporosis Treatmentmentioning

confidence: 99%

Applications of Calcium-Based Nanomaterials in Osteoporosis Treatment

Deng

Wei

Tang

2022

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

With rapidly aging populations worldwide, osteoporosis has become a serious global public health problem. Caused by disordered systemic bone remodeling, osteoporosis manifests as progressive loss of bone mass and microarchitectural deterioration of bone tissue, increasing the risk of fractures and eventually leading to osteoporotic fragility fractures. As fracture risk increases, antiosteoporosis treatments transition from nonpharmacological management to pharmacological intervention, and finally to the treatment of fragility fractures. Calcium-based nanomaterials (CBNMs) have unique advantages in osteoporosis treatment because of several characteristics including similarity to natural bone, excellent biocompatibility, easy preparation and functionalization, low pH-responsive disaggregation, and inherent pro-osteogenic properties. By combining additional ingredients, CBNMs can play multiple roles to construct antiosteoporotic biomaterials with different forms. This review covers recent advances in CBNMs for osteoporosis treatment. For ease of understanding, CBNMs for antiosteoporosis treatment can be classified as locally applied CBNMs, such as implant coatings and filling materials for osteoporotic bone regeneration, and systemically administered CBNMs for antiosteoporosis treatment. Locally applied CBNMs for osteoporotic bone regeneration develop faster than the systemically administered CBNMs, an important consideration given the serious outcomes of fragility fractures. Nevertheless, many innovations in construction strategies and preparation methods have been applied to build systemically administered CBNMs. Furthermore, with increasing interest in delaying osteoporosis progression and avoiding fragility fracture occurrence, research into systemic administration of CBNMs for antiosteoporosis treatment will have more development prospects. Deep understanding of the CBNM preparation process and optimizing CBNM properties will allow for increased application of CBNMs in osteoporosis treatments in the future.

show abstract

Bone targeted delivery of salmon calcitonin hydroxyapatite nanoparticles for sublingual osteoporosis therapy (SLOT)

Cited by 28 publications

References 47 publications

Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study

Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study

Overexpression of miR-29b Partially Rescued the Osteogenic Differentiation and Osteogenesis Ability of Ovx-BMSCs

Applications of Calcium-Based Nanomaterials in Osteoporosis Treatment

Contact Info

Product

Resources

About